Member Info for TrickyEFC

And all those sells at the end over the bid.

Bring on Wednesday.

After yesterday we can all do with some good blue.

Vol. Sold 66,249,712

Sold Value £138.78k

Vol. Bought 33,516,812

Bought Value £69.71k

So live trades we have 2 sells for every buy.

Volume of 142,363,781. So just over 42 million in delayed orders. Going of what we can see today do we all concur buyer in the House?

With that other delayed trade id say bunsennburber is right

Is that a 10 mill buy?

Dr Miele has been with company since 2011 and has been an integral player and would more than likely see MT-RNR1 and CYP2C19 ID Kits as his babies. Cheek been with company less than a year. Is it really bad news.😉💪

At this time maybe a Doctor is what the Doctor recommended what is best for GDR.

Further, Genedrive promoted Chief Scientific Officer Gino Miele to CEO. Miele has been with the company since 2011 and served as CSO since September.

Chair Ian Gilham said: ‘Gino has an unparallelled knowledge and understanding of the company, products and commercial strategies. I have every confidence that the leadership team, headed by Gino and strongly supported by our Chief Financial Officer, Russ Shaw, will lead genedrive to a successful future. I would like to thank James for his contributions at genedrive and, on behalf of the board, wish him well for the future.’

"Dr Gino Miele, previously chief scientific officer, has been appointed as the new CEO.

Miele, who joined Genedrive in 2011, has contributed to the development of the company's pharmacogenomic testing products.

He has overseen regulatory approvals in the UK, Europe, and the Middle East, and secured NICE approvals for the Genedrive MT-RNR1 and CYP2C19 ID Kits.

Miele also played a pivotal role in obtaining the FDA breakthrough device designation and is focused on expanding revenue opportunities in the UK and internationally

As for trading this at present not a chance. Only aim for me here is to accumulate at this moment in time. My aim here is to get as many as poss and hold. With everything going on here no plans of trading all about getting biggest position I am able too. I reckon my next buys will be at 0.15p or at 0.28p. either of those price points will do me.

Did you get the feeling yesterday the mms stopped any of the traders getting out at a profit.

We deserve for some of the gains to at least stick based on volume but as ya say 0.19 to 0.23 is all we get.

Being purely optimistic If it is Oberon selling then I feel we have a buyer waiting for their sells.

I still believe that the next holdings RNs is will be positive regardless of if it's a seller out or buyer in

It is hard to try finger out what they are up too.

But as you said new uncle the constant repeat cycle of this share now is not the action of a normal market.

What's the reason for this cycle is what we are all wanting to know. Also the fact that it's been this way since the last RNs gives off the feeling it ain't moving outta this range till next news. That's the frustrating part

Need to turn the other.... 😉

2% up in this market that deserves some

🐴🐴🐴🐴🐴

Daffy indeed it does

We shall find out soon new uncle, how soon is soon I don't know but it's gonna be soona than this time last week.

Logo

---

Aminoindane NCEs

About Awakn’s Aminoindane NCEs

Aminoindanes are a class of molecules that offer an alternative source of medical empathogens to MDMA for use alongside psycho-social support in the treatment of trauma related mental health disorders.

Aminoindanes have similar pharmacological properties to MDMA, they promote serotonin dopamine and noradrenaline release and block their reuptake. This combination of effects is believed to underpin the empathogenic activity. They offer a novel patentable approach to the treatment of trauma-related disorders.

Awakn acquired six years of proprietary research data from Prof. David Nutt, this data described potentially fast acting aminoindane compounds

Awakn has completed a Hit to Lead (HtL) program with Evotec. In vitro and in vivo data shows efficacy for drug-like hits, defining chemical series for lead optimization. Awakn has filed patents for two promising chemical series identified for lead optimization.

Sign Up for Newsletter

Email

First Name

Last Name

Awakn_logo_corp

HOME

ABOUT ADDICTION

R&D OVERVIEW

AWKN-001

AWKN-002

MDMA/ZYDIS

PARTNERSHIPS

INVESTOR RELATIONS

TEAM

CONTACT US

MEDIA

MAIN OFFICE

Awakn Life Sciences Corp

301-217 Queen St. W

Toronto, Ontario M5V 0R2

Canada

© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer

// ABOUT US SUB NAV // THERAPEUTIC FOCUS SUB NAV // R&D SUB NAV

Removed gas storage from UK

Turns out now people are realising the error of this.

Have look at government website December last year.

All about analysing how much storage would be needed to isolate UK from external influences.

MASSIVE once again government create a problem then suggest the solution.

💪💪💪

UK Gov funding coming.

Don't trust my post here do ya own research.

Net zero and all that.

Massive

Very tight so much those trades at 021 buys or sells 🤪🤔

Balls 😉